Ascletis Pharma Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

SEHK:1672 Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
09 Jan 25	BuyHK$916,439	Jinzi Jason Wu	Individual	300,000	HK$3.05
20 Nov 24	BuyHK$6,612,266	Jinzi Jason Wu	Individual	3,973,000	HK$1.66
04 Nov 24	BuyHK$8,717,650	Jinzi Jason Wu	Individual	6,043,000	HK$1.44

Insider Trading Volume

Insider Buying: 1672 insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of 1672?
Owner Type	Number of Shares	Ownership Percentage
Institutions	8,837,000	0.918%
General Public	122,450,263	12.7%
Private Companies	209,672,013	21.8%
Individual Insiders	622,167,724	64.6%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 12 shareholders own 87.29% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
53.5%	Jinzi Jason Wu	515,549,164	HK$2.1b	0%	no data
11%	Yang Dan	105,463,060	HK$421.9m	0%	no data
8.6%	Lakemont Holding Llc	82,827,414	HK$331.3m	0%	no data
6.51%	Jjw11 Limited	62,689,872	HK$250.8m	0%	no data
5.27%	CBC Investment Twelve Limited	50,729,518	HK$202.9m	0%	no data
1.39%	CBC Investment Fifteen Limited	13,425,209	HK$53.7m	0%	no data
0.34%	E Fund Management Co., Ltd.	3,285,000	HK$13.1m	0%	no data
0.24%	JP Morgan Asset Management	2,265,000	HK$9.1m	0%	no data
0.19%	China Universal Asset Management Company Ltd.	1,818,000	HK$7.3m	0%	no data
0.13%	Dimensional Fund Advisors LP	1,283,000	HK$5.1m	-50.3%	no data
0.12%	Hejingdao Wu	1,155,500	HK$4.6m	0%	no data
0.019%	American Century Investment Management Inc	186,000	HK$743.9k	0%	no data

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/02/04 21:56
End of Day Share Price	2025/02/04 00:00
Earnings	2024/06/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ascletis Pharma Inc. is covered by 6 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Ling Zhang	China Merchants Securities (HK) Co., Ltd
Mingrui Wang	Everbright Securities Co. Ltd.
Siao Ye	Everbright Securities Co. Ltd.